Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)

Journal of Clinical Hypertension

Volumn 15, Issue 8, 2013, Pages 542-554

  Margolis, Karen L ^a   Davis, Barry R ^b   Baimbridge, Charles ^b   Ciocon, Jerry O ^c   Cuyjet, Aloysius B ^d   Dart, Richard A ^e   Einhorn, Paula T ^f   Ford, Charles E ^b   Gordon, David ^f   Hartney, Thomas J ^g   Julian Haywood, L ^h   Holtzman, Jordan ^g   Mathis, David E ⁱ   Oparil, Suzanne ^j   Probstfield, Jeffrey L ^k   Simpson, Lara M ^b   Stokes, John D ^l   Wiegmann, Thomas B ^g   Williamson, Jeff D ^m  

^a Health Partners Institute for Education and Research   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c DEPARTMENT OF COLORECTAL SURGERY   (United States)

^d NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^e MARSHFIELD CLINIC   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h LAC USC MEDICAL CENTER   (United States)

ⁱ MERCER UNIVERSITY   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^l Christie Clinic   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CHLORTALIDONE; DOXAZOSIN; LISINOPRIL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTICHOLESTEREMIC AGENTS; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRAVASTATIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 84880734645     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12139     Document Type: Article

References (24)

1. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;1:342-360.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
3. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473-484.
4. Extension protocol: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. https://allhat.sph.uth.tmc.edu/Forms/ExtensionProtocol.pdf. Accessed March 15, 2013.
5. Margolis KL, Dunn K, Simpson LM, et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Am Heart J. 2009;158:948-955.
6. Cushman WC, Davis BR, Pressel SL, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich).2012;14:20-31.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
8. ALLHAT. http://allhat.sph.uth.tmc.edu/. Accessed March 15, 2013.
9. World Health Organization. Two-Way Translator for the Ninth and Tenth Revisions. Geneva: World Health Organization; 1997.
10. Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412-424.
11. Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 1995;75:1130-1134.
12. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
13. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359:1379-1387.
14. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771-777.
15. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929-2936.
16. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477-1486.
17. Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29:499-508.
18. Brouwers FP, Asselbergs FW, Hillege HL, et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J. 2011;161:1171-1178.
19. Maitland-van der ZA, Lynch A, Boerwinkle E, et al. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics. 2008;18:651-656.
20. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;2:CD007784.
21. Lewis DA, Emberson J, Blackwell L, et al. Effects of Lowering LDL-Cholesterol on Kidney Function: Meta-Analysis of Individual data from 130, 000 Participants in 22 Randomized Trials of Statin Therapy (poster board #: SA-PO219). Poster presentation at the American Society of Nephrology Annual Meeting, San Diego, CA, November 3, 2012.
22. Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777-784.
23. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the third National Health and Nutrition Examination Survey. Arch Intern Med. 2002;162:929-935.
24. Centers for Disease Control and Prevention (CDC). Disparities in screening for and awareness of high blood cholesterol-United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54:117-119.